微生物-宿主-同酵素分析により,微生物DPP4が潜在的な抗糖尿病標的であることが明らかになった
Kai Wang1,2, Zhiwei Zhang1,2, Jing Hang1,3,4
1Department of Physiology and Pathophysiology, School of Basic Medical Sciences, State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Peking University, Beijing, China.
まとめ
腸内微生物は,グルコース代謝を乱す酵素であるディペプチジルペプチダゼ4 (DPP4) を生成する. 新しい阻害剤であるダウリスリン-d4 (Dau-d4) は,選択的に微生物のDPP4を標的とし,マウスのグルコース耐性を改善します.
科学分野:
- 微生物学
- 代謝に関する研究
- 薬物の発見
背景:
- 腸内微生物と宿主の相互作用を理解することは,代謝の健康にとって極めて重要です.
- 微生物酵素は宿主の生理に大きく影響します
- ディペプチジルペプチダゼ4 (DPP4) はグルコースの調節に作用する.
研究 の 目的:
- ホストの生理学における腸内微生物由来酵素の役割を調査する.
- 微生物のDPP4をグルコース代謝に影響を与える酵素として特定する.
- 微生物のDPP4の選択的阻害剤を発見する.
主な方法:
- 微生物酵素の酵素活性スクリーニングプラットフォームの開発
- DPP4 を発現するバクテリアの分類を特定する
- 微生物の DPP4 阻害剤を検知する
主要な成果:
- 特定の細菌分類は,微生物のディペプチジルペプチダゼ4 (DPP4) を発現する.
- 微生物のDPP4は活性グルカゴン型ペプチド-1 (GLP-1) を減らし,マウスのグルコース代謝を阻害する.
- 既存のヒトのDPP4阻害剤 (例えばシタグリプチン) は,微生物のDPP4に対して無効である.
- ダウリソロン- d4 (Dau- d4) は選択的な微生物の DPP4 阻害剤として特定されました.
- Dau- d4は糖尿病のマウスのグルコース耐性を改善しました.
結論:
- 微生物のDPP4は,グルコース代謝の乱れに寄与する新しい要因です.
- 微生物のDPP4をターゲットにすることで,代謝疾患に対する潜在的な治療戦略が提供されます.
- Dau- d4は,代謝障害の治療のための選択的阻害剤として有望であることを示しています.
関連する概念動画
Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
208
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
208


